Imperial Innovations Group Plc, a UK technology transfer company, said that it has realised £9.5 million in cash following the sale of its portfolio company, Respivert Ltd, to the Johnson & Johnson subsidiary, Centocor Ortho Biotech Inc.
Imperial Innovations Group Plc, a UK technology transfer company, said that it has realised £9.5 million in cash following the sale of its portfolio company, Respivert Ltd, to the Johnson & Johnson subsidiary, Centocor Ortho Biotech Inc.